Radiation therapy for prostate cancer

Close metadata

Recommended articles:

Methodological aspects and effectiveness of stereotactic radiation therapy in hypofractionation mode in inoperable patients with non-small cell lung cancer. P.A. Herzen Journal of Oncology. 2024;(3):7-12

Results of the impact of personalized rehabilitation on the quality of life of men after laparoscopic prostatectomy. P.A. Herzen Journal of Oncology. 2024;(4):22-28

Hypofractionate radiotherapy for a rare malignant neoplasm of epidermal origin — keratoacanthoma of the skin. P.A. Herzen Journal of Oncology. 2024;(4):48-53

Potential of specialized diet therapy in reducing toxic manifestations in patients with metastatic castration-resistant prostate cancer with bone metastases during radionuclide therapy with radium chloride [223Ra]. P.A. Herzen Journal of Oncology. 2024;(6):33-41

Stereotactic high-dose irradiation for intramedullary metastases. Burdenko's Journal of Neurosurgery. 2024;(4):22-30

Patterns of CAF expression in tumors of the genitourinary system. Russian Journal of Archive of Pathology. 2024;(6):28-35

The paper considers the present state of radiation therapy for prostate cancer. It describes different radiotherapy technologies. There are data on the comparative efficiency and safety of various dose fractionation regimens. Based on the results of prospective and retrospective studies, the authors formulate indications for choosing optimal therapeutic approaches in relation to the biological characteristics and extent of a tumor process.

Keywords:

prostate cancer

conformal radiotherapy

stereotactic radiotherapy

high-dose-rate brachytherapy

Authors:

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

SPIN RSCI: 1759-8101
Scopus AuthorID: 6602709853
ResearcherID: K-1445-2014
ORCID: 0000-0001-8784-8415

Khmelevsky E.V.

P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia, Moscow, Russian Federation

Zubovskaya A.G.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Niushko K.M.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

List of references:

International Agency for Research on Cancer by Stewart BW, Wild CP. World Cancer Report 2014. Lyon; 2014:660-663.
Kaprin A, Starinskii V, Petrova G. Status of cancer care the population of Russia in 2014 [Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2014]. Moscow: MNIOI im. P.A. Gertsena — filial FGBU «NMIRTs» Rossii; 2015. (In Russ.)
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Version 1/2015.
Drodge CS, Boychak O, Patel S, Usmani N, Amanie J, Parliament MB et al. Acute toxicity of hypofractionated intensity-modulated radiotherapy for prostate cancer. Curr Oncol. 2015;22(2):e76-e84. doi:10.3747/co.22.2247.
Iksanova A, Sotnikov V, Pan’shin G. Hypofractionation in radiation therapy of prostate cancer. Meditsinskaya radiologiya i radiatsionnaya bezopasnost’. 2014;59(5):55-64. (In Russ.)
Tramacere F, Arcangeli S, Pignatelli A, Castagna R, Portaluri M. Hypofractionated dose escalated 3D conformal radiotherapy for prostate cancer: outcomes from a Mono-Institutional Phase II Study. Anticancer Res. 2015;35(5):3049-3054.
Nahum AE. The radiobiology of hypofractionation. Clin Oncol (R Coll Radiol). 2015;27(5):260-269. doi:10.1016/j.clon.2015.02.001.
Mangoni M, Desideri I, Detti B, Bonomo P, Greto D, Paiar F et al. Hypofractionation in prostate cancer: radiobiological basis and clinical appliance. Biomed Res Int. 2014;2014:781340. doi:10.1155/2014/781340.
De Bari B, Fiorentino A, Arcangeli S, Franco P, D'Angelillo RM, Alongi F. From radiobiology to technology: what is changing in radiotherapy for prostate cancer. Expert Rev Anticancer Ther. 2014;14(5):553-564. doi:10.1586/14737140.2014.883282.
King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC Jr. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009;73(4):1043-1048. doi:10.1016/j.ijrobp.2008.05.059.
Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol. 2011;6:3. doi:10.1186/1748-717X-6-3.
Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 2010;10:1. doi:10.1186/1471-2490-10-1.
King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. 2013;109(2):217-221. doi:10.1016/j.radonc.2013.08.030.
Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Technol Cancer Res Treat. 2010;9(6):575-582. doi:org/10.1177/153303461000900605.
Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250-1261. doi:10.1056/NEJMoa074311.
Dickinson PD, Malik J, Mandall P, Swindell R, Bottomley D, Hoskin P et al. Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK. BJU Int. 2014;113(5):748-753. doi:10.1111/bju.12358.
Pereira da Ponte Amadei L, Fernandes Silva JL, Hanna SA, Haddad CM, Nesrallah AJ, Carvalho HA. Biochemical control of prostate cancer with iodine-125 brachytherapy alone: experience from a single institution. Clin Transl Oncol. 2012;14(5):369-375. doi:10.1007/s12094-012-0810-6.
Lawton CA, Yan Y, Lee WR, Gillin M, Firat S, Baikadi M et al. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2012;82(5):e795-e801. doi:10.1016/j.ijrobp.2011.11.040.
Ghilezan MI. High-dose-rate brachytherapy as monotherapy for prostate cancer. Brachytherapy. 2014;13(6):529-541. doi:10.1016/j.brachy.2014.03.002.
Yoshioka Y, Suzuki O, Otani Y, Yoshida K, Nose T, Ogawa K. High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective. J Contemp Brachyther. 2014;6(1):91-98. doi:10.5114/jcb.2014.42026.
Kanaev S, Novikov S. The clinical significance of HDR brachytherapy patients with localized prostate cancer. Radiatsionnaya onkologiya i yadernaya meditsina. 2013;1:40-45. (In Russ.)
Barkati M, Williams SG, Foroudi F, Tai KH, Chander S, van Dyk S et al. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial. Int J Radiat Oncol Biol Phys. 2012;82(5):1889-1896. doi:10.1016/j.ijrobp.2010.09.006.
Hauswald H, Kamrava MR, Fallon JM, Wang PC, Park SJ, Van T et al. High-dose-rate monotherapy for localized prostate cancer: 10-year results. Int J Radiat Oncol Biol Phys. 2015;Aug 5. pii: S0360-3016(15)03101-6. doi:10.1016/j.ijrobp.2015.07.2290.
Potharaju M, Subramanaiam R, Venkataraman M, Perumal K, Ramakrishnan B, Vangara R, Reddy S. A report on the clinical outcome after high-dose rate (HDR) brachytherapy as monotherapy in early prostate cancer. Cureus. 2015;7(8):e303. doi:10.7759/cureus.303.
Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012;103(2):217-222. doi:10.1016/j.radonc.2012.01.007.
Bece A, Patanjali N, Jackson M, Whitaker M, Hruby G. High-dose rate brachytherapy boost for prostate cancer: Outcomes and genitourinary toxicity. Brachytherapy. 2015;14(5):670-676. doi:10.1016/j.brachy.2015.04.004.
Yamada Y, Kollmeier MA, Pei X, Kan CC, Cohen GN, Donat SM et al. A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. Brachytherapy. 2014;13(2):111-116. doi:10.1016/j.brachy.2013.11.005.
Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008;299(23):2760-2769. doi:10.1001/jama.299.23.2760.
Grishina Yu, Khmelevskii E. Radiotherapy for local recurrences of prostate cancer after radical prostatectomy. Voprosy Onkologii. 2015;61(1):7-13. (In Russ.)
Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N et al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol. 2014;32(35):3939-3947. doi:org/10.1200/jco.2013.54.7893.
Kaplan JR, Kowalczyk KJ, Borza T, Gu X, Lipsitz SR, Nguyen PL et al. Patterns of care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy. BJU Int. 2013;111(8):1208-1214. doi:org/10.1111/bju.12079.
Howell DD, James JL, Hartsell WF, Suntharalingam M, Machtay M, Suh JH et al. Single-fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases-equivalent efficacy, less toxicity, more convenient: a subset analysis of Radiation Therapy Oncology Group trial 97-14. Cancer. 2013;119(4):888-896. doi:10.1002/cncr.27616.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. ALSYMPCA Investigators. N Engl J Med. 2013;369(3):213-223. doi:10.1056/NEJMoa1213755.
Shore ND. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective. Urology. 2015;85(4):717-724. doi:10.1016/j.urology.2014.11.031.
Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A, Giammarile F. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging. 2008;35(10):1934-1940. doi:10.1007/s00259-008-0841-y.
Cheetham PJ, Petrylak DP. Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation. Oncology. 2012;26(4):330-337, 341.
Anido Herranz U, Fernández Calvo O, Afonso Afonso FJ, Rodríguez Martínez de Llano S, Lázaro Quintela M, León Mateos L et al. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. Expert Rev. Anticancer Ther. 2015;15(3):339-348. doi:10.1586/14737140.2015.999045.
Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27(15):2436-2442. doi:10.1200/JCO.2008.20.4164.
Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27(20):3319-3324. doi:10.1200/JCO.2008.20.5393.
Morris MJ, Hammers HJ, Sweeney C, Antonarakis ES, Cho SY et al. Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): a phase I Prostate Cancer Clinical Trials Consortium Study. J Clin Oncol. 2013;31(Suppl.):abstr.5021. (ASCO Meeting Abstracts).

Close metadata